Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | GMNN | O75496 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 5/20 | 0.30 |
| ▸ | RARA | P10276 | 4/20 | 0.30 |
| ▸ | RARB | P10826 | 4/20 | 0.30 |
| ▸ | RARG | P13631 | 4/20 | 0.30 |
| ▸ | RXRB | P28702 | 2/20 | 0.30 |
| ▸ | RXRG | P48443 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18582451 | 1.00 | MAPT (0.56) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL2837999 | 0.94 | MAPT (0.61) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL30002204 | 0.94 | MAPT (0.61) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL2832598 | 0.88 | MAPT (0.76) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL545399 | 0.88 | MAPT (0.76) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL2840387 | 0.87 | MAPT (0.53) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL2836348 | 0.85 | ALOX15 (0.54) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL2952241 | 0.82 | ALOX15 (0.49) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL2841013 | 0.79 | MAPT (0.67) | MAPTLMNAHIF1AGMNNPMP22 | |
| SCHEMBL42982 | 0.79 | MAPT (0.67) | MAPTLMNAHIF1AGMNNPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013144595-A1 | PERIDININ-CHLOROPHYLL BINDING PROTEINS | PROTEIN TECHNOLOGIES LIMITED (GB) | 2013-10-03 | — | — | WO | claimed |
| WO-2024141918-A1 | USE OF MICROALGAE AND MICROALGAE DERIVED COMPONENTS IN CULTIVATED FOOD PRODUCTION | WEFORESEA LTD. (IL) | 2024-07-04 | — | — | WO | disclosed |
| US-20240191053-A1 | SYSTEMS, MICROORGANISMS, OR METHODS FOR WASTE PET VALORIZATION | WASHINGTON UNIVERSITY (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240165036-A1 | ENCAPSULATED VITAMIN D | Nulixir Inc. | 2024-05-23 | — | — | US | disclosed |
| US-20240065262-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY HANSON (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240033287-A1 | ANTIMICROBIAL CLAY COMPOSITIONS AND METHODS OF USING | ELANCO US INC (US) | 2024-02-01 | — | — | US | disclosed |
| US-20240024358-A1 | THERAPEUTIC CLAY COMPOSITIONS AND METHODS OF USING | ELANCO US, Inc. | 2024-01-25 | — | — | US | disclosed |
| US-20230404126-A1 | ENCAPSULATED PRECURSORS OF NICOTINAMIDE ADENINE DINUCLEOTIDE AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-12-21 | — | — | US | disclosed |
| US-20230371551-A1 | FEED ADDITIVE COMPOSITIONS | ELANCO US INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3716958-B1 | COMPOSITION FOR THE TREATMENT OF DYSBIOSIS OF THE INTESTINAL MICROBIOTA | DERMAPHARM AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-20050065097-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMA, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CPT1A, TXNRD2, PC | MAPT 4758/4885LMNA 1111/4885HIF1A 1596/4885 |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | MAPT 4813/4885LMNA 29/4885HIF1A 2345/4885 |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | MAPT 4766/4885LMNA 34/4885HIF1A 2311/4885 |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | TTPA, PROC, RBP4 | MAPT 3857/4885LMNA 3024/4885HIF1A 4080/4885 |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | RBP1, PROC, RBP4 | MAPT 3997/4885LMNA 2708/4885HIF1A 3872/4885 |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | MAPT 3961/4885LMNA 716/4885HIF1A 4172/4885 |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | PROC, TTPA, CYC1 | MAPT 4035/4885LMNA 2351/4885HIF1A 4422/4885 |
| US-20050065097-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | TXNRD2, GPX4, PC | MAPT 4751/4885LMNA 868/4885HIF1A 1781/4885 |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | NFE2L2, GPX4, CYP11B2 | MAPT 4360/4885LMNA 685/4885HIF1A 2693/4885 |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | MAPT 3908/4885LMNA 870/4885HIF1A 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.